Cardiomyocyte protection by hibernating brown bear serum: towards the identification of new protective molecules against myocardial infarction
Ischemic heart disease remains one of the leading causes of death worldwide. Despite intensive research on the treatment of acute myocardial infarction, no effective therapy has shown clinical success. Therefore, novel therapeutic strategies are required to protect the heart from reperfusion injury....
Published in: | Frontiers in Cardiovascular Medicine |
---|---|
Main Authors: | , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2021
|
Subjects: | |
Online Access: | https://hdl.handle.net/11250/2999552 https://doi.org/10.3389/fcvm.2021.687501 |
id |
fthsinnlandet:oai:brage.inn.no:11250/2999552 |
---|---|
record_format |
openpolar |
spelling |
fthsinnlandet:oai:brage.inn.no:11250/2999552 2024-03-03T08:49:18+00:00 Cardiomyocyte protection by hibernating brown bear serum: towards the identification of new protective molecules against myocardial infarction Givre, Lucas Da Silva, Claire Crola Swenson, Jon Arnemo, Jon Martin Gauquelin-Koch, Guillemette Bertile, Fabrice Lefai, Etienne Gomez, Ludovic 2021 application/pdf https://hdl.handle.net/11250/2999552 https://doi.org/10.3389/fcvm.2021.687501 eng eng Frontiers in Cardiovascular Medicine. 2021, 8 . urn:issn:2297-055X https://hdl.handle.net/11250/2999552 https://doi.org/10.3389/fcvm.2021.687501 cristin:1956126 Navngivelse 4.0 Internasjonal http://creativecommons.org/licenses/by/4.0/deed.no 8 Frontiers in Cardiovascular Medicine 687501 cardiomyocyte hypoxia-reoxygenation injury protection bear serum hibernation novel therapeutic strategy VDP::Matematikk og Naturvitenskap: 400 Peer reviewed Journal article 2021 fthsinnlandet https://doi.org/10.3389/fcvm.2021.687501 2024-02-02T12:42:33Z Ischemic heart disease remains one of the leading causes of death worldwide. Despite intensive research on the treatment of acute myocardial infarction, no effective therapy has shown clinical success. Therefore, novel therapeutic strategies are required to protect the heart from reperfusion injury. Interestingly, despite physical inactivity during hibernation, brown bears (Ursus arctos) cope with cardiovascular physiological conditions that would be detrimental to humans. We hypothesized that bear serum might contain circulating factors that could provide protection against cell injury. In this study, we sought to determine whether addition of bear serum might improve cardiomyocyte survival following hypoxia–reoxygenation. Isolated mouse cardiomyocytes underwent 45 min of hypoxia followed by reoxygenation. At the onset of reoxygenation, cells received fetal bovine serum (FBS; positive control), summer (SBS) or winter bear serum (WBS), or adult serums of other species, as indicated. After 2 h of reoxygenation, propidium iodide staining was used to evaluate cell viability by flow cytometry. Whereas, 0.5% SBS tended to decrease reperfusion injury, 0.5% WBS significantly reduced cell death, averaging 74.04 ± 7.06% vs. 79.20 ± 6.53% in the FBS group. This cardioprotective effect was lost at 0.1%, became toxic above 5%, and was specific to the bear. Our results showed that bear serum exerts a therapeutic effect with an efficacy threshold, an optimal dose, and a toxic effect on cardiomyocyte viability after hypoxia–reoxygenation. Therefore, the bear serum may be a potential source for identifying new therapeutic molecules to fight against myocardial reperfusion injury and cell death in general. publishedVersion Article in Journal/Newspaper Ursus arctos Høgskolen i Innlandet: Brage INN Frontiers in Cardiovascular Medicine 8 |
institution |
Open Polar |
collection |
Høgskolen i Innlandet: Brage INN |
op_collection_id |
fthsinnlandet |
language |
English |
topic |
cardiomyocyte hypoxia-reoxygenation injury protection bear serum hibernation novel therapeutic strategy VDP::Matematikk og Naturvitenskap: 400 |
spellingShingle |
cardiomyocyte hypoxia-reoxygenation injury protection bear serum hibernation novel therapeutic strategy VDP::Matematikk og Naturvitenskap: 400 Givre, Lucas Da Silva, Claire Crola Swenson, Jon Arnemo, Jon Martin Gauquelin-Koch, Guillemette Bertile, Fabrice Lefai, Etienne Gomez, Ludovic Cardiomyocyte protection by hibernating brown bear serum: towards the identification of new protective molecules against myocardial infarction |
topic_facet |
cardiomyocyte hypoxia-reoxygenation injury protection bear serum hibernation novel therapeutic strategy VDP::Matematikk og Naturvitenskap: 400 |
description |
Ischemic heart disease remains one of the leading causes of death worldwide. Despite intensive research on the treatment of acute myocardial infarction, no effective therapy has shown clinical success. Therefore, novel therapeutic strategies are required to protect the heart from reperfusion injury. Interestingly, despite physical inactivity during hibernation, brown bears (Ursus arctos) cope with cardiovascular physiological conditions that would be detrimental to humans. We hypothesized that bear serum might contain circulating factors that could provide protection against cell injury. In this study, we sought to determine whether addition of bear serum might improve cardiomyocyte survival following hypoxia–reoxygenation. Isolated mouse cardiomyocytes underwent 45 min of hypoxia followed by reoxygenation. At the onset of reoxygenation, cells received fetal bovine serum (FBS; positive control), summer (SBS) or winter bear serum (WBS), or adult serums of other species, as indicated. After 2 h of reoxygenation, propidium iodide staining was used to evaluate cell viability by flow cytometry. Whereas, 0.5% SBS tended to decrease reperfusion injury, 0.5% WBS significantly reduced cell death, averaging 74.04 ± 7.06% vs. 79.20 ± 6.53% in the FBS group. This cardioprotective effect was lost at 0.1%, became toxic above 5%, and was specific to the bear. Our results showed that bear serum exerts a therapeutic effect with an efficacy threshold, an optimal dose, and a toxic effect on cardiomyocyte viability after hypoxia–reoxygenation. Therefore, the bear serum may be a potential source for identifying new therapeutic molecules to fight against myocardial reperfusion injury and cell death in general. publishedVersion |
format |
Article in Journal/Newspaper |
author |
Givre, Lucas Da Silva, Claire Crola Swenson, Jon Arnemo, Jon Martin Gauquelin-Koch, Guillemette Bertile, Fabrice Lefai, Etienne Gomez, Ludovic |
author_facet |
Givre, Lucas Da Silva, Claire Crola Swenson, Jon Arnemo, Jon Martin Gauquelin-Koch, Guillemette Bertile, Fabrice Lefai, Etienne Gomez, Ludovic |
author_sort |
Givre, Lucas |
title |
Cardiomyocyte protection by hibernating brown bear serum: towards the identification of new protective molecules against myocardial infarction |
title_short |
Cardiomyocyte protection by hibernating brown bear serum: towards the identification of new protective molecules against myocardial infarction |
title_full |
Cardiomyocyte protection by hibernating brown bear serum: towards the identification of new protective molecules against myocardial infarction |
title_fullStr |
Cardiomyocyte protection by hibernating brown bear serum: towards the identification of new protective molecules against myocardial infarction |
title_full_unstemmed |
Cardiomyocyte protection by hibernating brown bear serum: towards the identification of new protective molecules against myocardial infarction |
title_sort |
cardiomyocyte protection by hibernating brown bear serum: towards the identification of new protective molecules against myocardial infarction |
publishDate |
2021 |
url |
https://hdl.handle.net/11250/2999552 https://doi.org/10.3389/fcvm.2021.687501 |
genre |
Ursus arctos |
genre_facet |
Ursus arctos |
op_source |
8 Frontiers in Cardiovascular Medicine 687501 |
op_relation |
Frontiers in Cardiovascular Medicine. 2021, 8 . urn:issn:2297-055X https://hdl.handle.net/11250/2999552 https://doi.org/10.3389/fcvm.2021.687501 cristin:1956126 |
op_rights |
Navngivelse 4.0 Internasjonal http://creativecommons.org/licenses/by/4.0/deed.no |
op_doi |
https://doi.org/10.3389/fcvm.2021.687501 |
container_title |
Frontiers in Cardiovascular Medicine |
container_volume |
8 |
_version_ |
1792506499808886784 |